Choosing a Contract Manufacturing Partner for Complex Biologics

Biopharmaceutical development has become much more complicated than it was even a few years ago. Contract manufacturing organizations are no longer judged only by available capacity, production timelines or facility scale. Many development programs now involve highly complex therapies such as antibody-drug conjugates, bispecific antibodies and radiopharmaceuticals, where biology, chemistry, analytics and manufacturing decisions are tightly connected from the beginning. In these programs, delays often happen not because the science fails, but because different stages of development stop moving in sync.

For executives choosing a contract manufacturing partner, the real question is no longer whether a provider can manufacture a process after it has already been transferred. The more important issue is whether the organization can help shape that process early enough to prevent expensive problems later. Many biotech companies enter development with evolving data, uncertain manufacturability and changing clinical priorities. A strong partner should be able to work through those uncertainties alongside the client instead of simply waiting for a finalized process package to arrive.

That is especially important in complex biologics and conjugate programs, where process development and analytical work cannot operate in isolation. If teams discover too late that a method, impurity profile or control strategy does not support the next clinical or regulatory milestone, timelines can slip quickly. Companies evaluating manufacturing partners should pay close attention to how integrated the technical teams actually are. The best organizations tend to use analytics as an active part of development decision-making rather than treating it mainly as a compliance function.

Regulatory preparation is also becoming more connected to early technical decisions. IND packages, comparability planning and later-stage manufacturing readiness all depend on how development work is structured from the start. That means biotech companies increasingly benefit from manufacturing partners that understand not only GMP execution, but also how regulators evaluate newer therapeutic modalities and what kinds of data packages are likely to matter later in development.

For smaller biotech companies, the engagement model itself can become just as important as the technical capabilities. Early-stage programs often need flexibility, direct scientific access and close collaboration because development priorities can shift quickly as new data emerges. Large manufacturing organizations may offer significant scale, but emerging programs can struggle if they become just another project moving through a large operational system. Many executives therefore look for partners that remain closely involved as programs evolve and can support continuity across development stages rather than handing work from one disconnected group to another.

In practice, the strongest manufacturing relationships are usually the ones that help reduce technical friction and preserve momentum as programs move toward the clinic. That continuity can save companies a significant amount of time, cost and redevelopment effort later.

Abzena has built its model around that more integrated approach to complex biologics and bioconjugates. The company works across antibody discovery and engineering, cell line development, process and analytical development, cGMP biologics manufacturing and clinical-to-commercial bioconjugate production. Its experience is particularly relevant for ADCs, AOCs, RDCs and multispecific antibody programs, where coordination across antibodies, payloads, linkers and conjugation strategies becomes critical. For biotech organizations developing technically demanding therapeutic assets, Abzena offers a manufacturing and development model designed to keep scientific, analytical and production work aligned as programs scale.